#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

June 2, 2026

AI Summary

5 min read

In the summer of 2024, Strand Therapeutics put its first three patients on a Phase 1 trial for a new kind of cancer drug. Eighteen months later, two of those three were still on the trial. One of them, a patient with stage four melanoma that had spread to the lungs, bones, and other organs, had been riddled with tumors visible all over a body scan. After treatment, the scan showed no detectable lesions. The patient, who had exhausted every other option, was still alive a year and a half later. That image—before and after—became the centerpiece of a pitch that would, within two months, help land the company’s core policy idea in the President’s legislative priorities.

The Mechanism: Making Tumors Scream

Strand’s technology is built on a simple but elusive idea in genetic medicine. Instead of trying to block a cancer’s ability to hide from the immune system—the approach behind blockbuster drugs like Keytruda—Strand delivers instructions directly into cancer cells, tricking them into sending out an activation signal that says, “I am a foreign object, please come eat me.” This is not a new concept in immunology; it dates back to the 1990s. The problem has always been delivery. Previous attempts to inject artificial signals into tumors failed because the signal dissipated too quickly or activated the immune system in the wrong places, causing toxicity.

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

Never miss an episode of The Tim Ferriss Show

Get every new episode summarized in your inbox — free, ~5 minutes to read.

No spam. Unsubscribe anytime.

What you'll learn

1 (00:00) **Strand's genetic medicine breakthrough** - First-in-class data showing systemic abscopal responses in deep organ metastases
2 (01:00) **Experimental format introduction** - Tim explains "Tim's Founder Kitchen" as recorded brainstorming sessions with founders
3 (05:22) **Jake's background and mission** - Technical founder-CEO whose identity is tied to Strand's success
4 (08:20) **Initial dinner context** - Boston meeting with other biotech CEOs that sparked Tim's interest
5 (11:10) **Patient case deep dive** - Before-and-after scans and Kaplan-Meier curve interpretation
6 (18:05) **Drug vs. product distinction** - Why ex-vivo cell therapy is a good drug but poor product due to cost and logistics
7 (24:44) **Abscopal effect explained** - Mechanism allowing injected tumors to trigger systemic immune responses

+ Full timestamped outline available in the app

Show Notes

Jake Becraft is the CEO and co-founder of Strand Therapeutics, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.

This episode is brought to you by:

Helix Sleep premium mattresses: HelixSleep.com/Tim (20% off any purchase)
Incogni, which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: Incogni.com/Tim (use code TIM at checkout and get 60% off an annual plan)

Timestamps:

[00:00:00] Start.
[00:06:07] What Strand does.
[00:08:19] The Boston dinner.
[00:11:05] The image of a body riddled with cancer.
[00:15:05] What stuck for the muggles in the pitch deck.
[00:17:14] A good drug vs. a good product.
[00:19:40] Tricking cancer into snitching on itself.
[00:27:38] The abscopal effect.
[00:34:04] Potency, specificity, and delivery.
[00:35:46] First principles thinking.
[00:36:38] The precipice of a revolution.
[00:41:14] The thousand people in the room.
[00:48:38] Psychedelic medicine as a cautionary tale.
[00:51:17] What actually catches a policymaker’s attention.
[00:53:42] Breakthrough vs. incremental.
[00:54:55] What’s in it for the policymakers?
[00:58:08] The 80/20 wish list.
[01:01:31] Australia’s CTN system.
[01:03:51] Sheep, psychedelics, and red-tape arbitrage.
[01:05:22] China’s clinical-trial flywheel vs. slow-motion American loss.
[01:06:53] The bicoastal biotech ethos.
[01:08:10] Can the FDA actually pull this off?
[01:12:12] The Sophie’s Choice of pharma development.
[01:14:16] Lost arts of founder mode.
[01:15:23] Rockets for tumors, T-cells, and beyond.
[01:19:16] Viral in policy circles.
[01:23:09] The Washington Post headline and the PickFu split test.
[01:27:56] Solution-first storytelling.
[01:33:54] RNA medicine and platform therapeutics.
[01:39:17] Moderna